Eccrine squamous syringometaplasiaL73.2

Hurt et al. 1990

Differently defined histological (and clinical) term for a (non-specific) reactive proliferation of ductal sweat gland cells Such sweat gland proliferations can occur within the framework of infiltrative processes in T-cell lymphomas. But also in malignant epithelial tumours of the skin (e.g. basal cell carcinoma) or in other displacing skin processes such as morphea. Carrascosa R et al. reported about the coincidence of "Ekkriner squamous syringometaplasia" with a graft-versus-host reaction. This is probably an analogous mechanism to that of plaquelike morphea (Carrascosa R et al. 2014).

Furthermore, reactive proliferation of ductal sweat gland cells is found in neutrophilic eccrine hidradenitis.

A third eruptive form is the "eccrine squamous syringometaplasia" after chemotherapy, which occurs in both adulthood and childhood. Lescoat A et al. reported an eruptive occurrence after use of the BRAF inhibitor vemurafenib (Lescoat A et al. 2013). This form is also known as "chemotherapy-induced eccrine squamous syringometaplasia".

Children and adults, more often after chemotherapy

Clinically, chemotherapeutically induced eccrine squamous syringometaplasia is characterized by eruptive red nodules and plaques that appear in the axillae, inguinal region and other body folds. The clinic is uncharacteristic so that the diagnosis can only be made after a biopsy. The eccrine squamous syringometaplasia in displacing growing processes of the skin are histological accidental findings and accordingly no clinical-morphological findings. Nethers K et al. reported on an "Eccrine squamous syringometaplasia" in a chemotherapeutically treated patient (chronic myeloid leukemia) after administration of a "granulocyte-colony stimulating factor" (G-CSF).

El-Fidawi G et al. found this type of reaction in a plaqueform morphea.

1. Bittar PG et al (2018) Chemotherapy-induced eccrine squamous syringometaplasia in an infant. Pediatric Dermatol 35:e84-e85.
2. Carrascosa R et al (2014) Coexistence of eccrine squamous syringometaplasia and graft-versus-host disease in a patient with secondary myelodysplastic syndrome. Acta Derm Venereol 94:599-600.
3. El-Fidawi G et al (2014) Eccrine squamous syringometaplasia in a patient with plaque-type morphea. J Cutan pathogen 41:548-549.
4. Lescoat A et al. (2013) Vemurafenib-induced eccrine squamous syringometaplasia. Dermatology 226:362-364.
5. Nethers K et al (2017) Eccrine squamous syringometaplasia in an allogenic stem cell transplant patient undergoing chemotherapy. Dermatol Online J 23(9). pii: 13030/qt61w0f2kd.